02:00 Tue 29 Dec 2020
Abingdon Health PLC - AbC-19TM Rapid Test Update
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM
AbC-19TM Rapid Test Update
Abingdon continues to liaise with the
Whereas the DHSC has right of first refusal for supplies of the AbC-19TM Rapid Test, the Company's regulatory department is liaising with regulatory authorities in other jurisdictions around the world to allow use of the product. For example, to allow the continued validity of the current CE marking post Brexit, Abingdon Health, as legal manufacturer via its agent, has successfully registered the AbC-19 Rapid Test with the Maltese Medicines Authority. This means that the CE mark, for professional use, will continue to apply across the European Union after
Enquiries:
Abingdon Heath plc |
|
|
|
Chief Executive Officer |
Via Consilium |
|
Non-Executive Chairman |
|
|
Finance Director |
|
|
|
|
N+1 Singer |
Sole Broker and NOMAD |
Tel: +44 (0) 20 7496 3000 |
|
|
|
|
|
|
|
|
|
Consilium |
Financial PR |
Tel: +44 (0) 7720 088 468 |
|
|
|
|
|
|
|
|
|
About Abingdon Health
Established in 2008, Abingdon Health is a lateral flow diagnostics company providing contract service solutions to a global client base in the healthcare sector and other industries. Services offered by the Company to its clients including product development, regulatory support, technology transfer and commercial manufacturing.
The Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for Covid-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The Company is also working on the transfer of customers' Covid-19 antigen tests to manufacture, and is also manufacturing a component of a rapid PCR (polymerase chain reaction) test. The Company also produces lateral flow tests covering non-Covid-19 applications in areas such as infectious disease, oncology, animal health and environmental testing.
The Company's main country of operation is the
For more information visit www.abingdonhealth.com
About
The
About AbC19™ Rapid Test
The AbC-19TM IgG lateral flow assay is targeted at IgG antibodies to the full spike protein of SARS-CoV-2 (COVID19) to indicate a measure of immune response (aligned with neutralizing antibodies).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE